Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.98% and 0.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q3 Earnings and Revenues Top Estimates

Becton, Dickinson (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Becton, Dickinson (BDX) Ahead of Earnings?

Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

Delta Air Lines

DISH Network

Ford Motor Company

Global Payments

Hilton Worldwide Holdings

IQVIA Hlds

Kinder Morgan

AT&T

Xerox

Low-valuation, high-leveraged stocks have led the market in recent months and are poised to outperform.

10 Bargain Blue Chips Seen Surging As Fed Lowers Rates

Abbott Labs

Baxter

Boston Scientific

Edwards Lifesciences

Illumina

Intuitive Surgical

Johnson & Johnson

Medtronic

Stryker

Market caps for these medical device stocks are big. Most of them have been big winners, too.

10 Biggest Medical Device Stocks

Bio-Rad Laboratories

Thermo Fisher Scientific

In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.

IVD Market Sustains Momentum: 3 Stocks in Focus

Celgene

Cigna

CVS Health

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

5 Health Care Stocks in Gurus’ Portfolios

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock?

Why Is Becton Dickinson (BDX) Up 3.7% Since Last Earnings Report?

Royal Philips

The Food and Drug Administration likely won't pull medical devices coated in chemotherapy drug paclitaxel from the market, an analyst said Thursday. But it could require additional studies.

Why The FDA Likely Won't Pull These Medical Devices From The Market

Things should pick up in the back half of the fiscal year.

Becton, Dickinson Muscles Through a Tough Quarter

Becton Dickinson and Co’s stock has lost more than 10 percent since March 15 in response to the FDA update on drug-coated balloons, or DCBs.

Barclays Upgrades Becton Dickinson, Says Market Overreacted To FDA's Drug-Coated Balloon Update

Becton Dickinson and Co (BDX) CEO Vince Forlenza on Q2 2019 Results - Earnings Call Transcript

Shares of Becton Dickinson & Co. dropped 3.1% in morning trade Thursday, after the medical technology company topped fiscal second-quarter profit expectations, but slashed its full-year outlook, citing "recent regulatory and market pressures related to paclitaxel-coated devices.

Becton Dickinson's stock drops after profit, revenue growth outlook cut

Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.

Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y

Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.78% and -0.98%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q2 Earnings Beat Estimates

Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.

Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?

Schlumberger

The Zacks Research Daily presents the best research output of our analyst team.

Top Analyst Reports for Celgene, Schlumberger & Becton, Dickinson

Amgen

Quest Diagnostics

Gilead Sciences

While the overall stock market has been very strong year to date, with sectors like technology outperforming, the health care sector, which encompasses everything from pharmaceuticals to biotech to medical devices and more, has been absolutely wretched, lagging the S&P 500 by a huge 9%.

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

Chevron

Lincoln Electric Hlds

National Retail Properties

if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.

Dividend Growth Stocks With Upside To Analyst Targets

BD introduces new FDA cleared product to lower the risk of sepsis and combat platelet contamination.

BD Introduces New Product to Reduce the Risk of Sepsis

Becton, Dickinson announces the FDA premarket approval for Venovo venous stent device.

Here's Why You Should Hold Becton, Dickinson Stock for Now

Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.

BD Remains Confident About LUTONIX DCB Despite FDA Letter

Emerson Electric

Sysco

V.F.

To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years.

Dividend Aristocrats With Capital Gains

Becton, Dickinson receives a number of regulatory approvals of late.

BD's Venovo Gets FDA Nod, Interventional Arm to Get a Boost

General Dynamics

Kimberly-Clark

People's United Financial

PepsiCo

The stock market is way up and ironically, that’s terrible news for us dividend investors. Yields are in the tank yet again. The S&P 500 pays a measly 1.9% today. If you have a million-dollar portfolio, that’s a lousy $19,000 per year in income. Pathetic.

News for Becton, Dickinson and Co. Stock (BDX)